Cheap blood drug could
prevent thousands of maternal deaths in developing world
Send a link to a friend
[April 27, 2017] By
Kate Kelland
LONDON (Reuters) - A cheap and widely
available drug could save the lives of one in three of the 100,000 new
mothers who bleed to death after childbirth every year, mostly in poorer
countries, according to the first study of its use in postpartum
haemorrhage.
|
In a trial of 20,000 women, researchers found that the drug, called
tranexamic acid or TXA, cut the number of deaths due to post-partum
bleeding by 31 percent if given within three hours. The treatment
costs about $2.50 in most countries, they said.
As TXA works by stopping blood clots from breaking down, the
researchers also found that it reduced the need for urgent surgery
to control bleeding by more than a third.
"It's safe, affordable and easy to administer, and we hope that
doctors will use it as early as possible following the onset of
severe bleeding after childbirth," said Haleema Shakur, an associate
professor at the London School of Hygiene & Tropical Medicine (LSHTM)
who co-led the trial.
The study involved mothers from 193 hospitals in 21 countries,
mainly in Africa and Asia but also in Britain and elsewhere, who
suffered postpartum haemorrhage (PPH), the leading cause of maternal
death worldwide.
PPH is defined as a blood loss of more than 500 milliliters within
24 hours of giving birth.
The results showed that of the women given tranexamic acid within
three hours, 89 died from bleeding compared with 127 given the
normal standard care plus a placebo. No side effects from the drug
were found for either mothers or babies.
[to top of second column] |
TXA, which is now an off-patent generic medicine, was originally
invented in the 1960s by a Japanese husband and wife research team,
Shosuke and Utako Okamoto. The drug is widely used to treat
excessive blood loss from major trauma injuries.
They had hoped it would be used to reduce deaths from PPH, but
according to the LSHTM experts who ran this study, they were unable
to persuade obstetricians at the time to conduct a trial.
(Editing by Louise Ireland)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|